Iñaki Imaz-Iglesia

Dr. Iñaki Imaz-Iglesia

Institute for Health Carlos III
+1
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2008 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
IIIñaki Imaz-Iglesia
Iñaki Imaz-Iglesia
CMCarmen Martínez-Cervell
Carmen Martínez-Cervell
EGElvira Elena García-Álvarez
Elvira Elena García-Álvarez
JSJuan Manuel Sendra-Gutiérrez
Juan Manuel Sendra-Gutiérrez
JGJesús González-Enríquez
Jesús González-Enríquez

1 November 2014 in JACC
Verified
Journal Article
Closed access
JCJosé M. Castellano
José M. Castellano
GSGinés Sanz
Ginés Sanz
JPJose Penalvo
Jose Penalvo
SBSameer Bansilal
Sameer Bansilal
AFAntonio Fernandez-Ortiz
Antonio Fernandez-Ortiz
VFValentin Fuster
Valentin Fuster

5 December 2009 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
IIIñaki Imaz-Iglesia
Iñaki Imaz-Iglesia
PZP. Zegarra
P. Zegarra
JGJ. González-Enríquez
J. González-Enríquez
BRB. Rubio
B. Rubio
RAR. Alcazar
R. Alcazar
JAJ. M. Amate
J. M. Amate

1 March 2020 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Closed access
EGEsther García-Carpintero
Esther García-Carpintero
MCMontserrat Carmona
Montserrat Carmona
JCJuan Pablo Chalco-Orrego
Juan Pablo Chalco-Orrego
JGJesús González-Enríquez
Jesús González-Enríquez
IIIñaki Imaz-Iglesia
Iñaki Imaz-Iglesia

1 August 2015 in Acta Tropica
Verified
Journal Article
Closed access
IIIñaki Imaz-Iglesia
Iñaki Imaz-Iglesia
LMLucía García-San Miguel
Lucía García-San Miguel
LAL. Eduardo Ayala-Morillas
L. Eduardo Ayala-Morillas
LGLidia García-Pérez
Lidia García-Pérez
JGJesús González-Enríquez
Jesús González-Enríquez
ASAntonio Sarria-Santamera
Antonio Sarria-Santamera

6 May 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
CSCecilia Superchi
Cecilia Superchi
FBFlorie Brion Bouvier
Florie Brion Bouvier
CGChiara Gerardi
Chiara Gerardi
MCMontserrat Carmona
Montserrat Carmona
LMLorena San Miguel
Lorena San Miguel
RPRaphaël Porcher
Raphaël Porcher
Objective Personalised medicine (PM) allows treating patients based on their individual demographic, genomic or biological characteristics for tailoring the ‘right treatment for the right person at the right time’. Robust methodology is required for PM clinical trials, to correctly identify groups of participants and treatments. As an initial step for the development of new recommendations on trial designs for PM, we aimed to present an overview of the study designs that have been used in this field. Design Scoping review. Methods We searched (April 2020) PubMed, Embase and the Cochrane Library for all reports in English, French, German, Italian and Spanish, describing study designs for clinical trials applied to PM. Study selection and data extraction were performed in duplicate resolving disagreements by consensus or by involving a third expert reviewer. We extracted information on the characteristics of trial designs and examples of current applications of these approaches. The extracted information was used to generate a new classification of trial designs for PM. Results We identified 21 trial designs, 10 subtypes and 30 variations of trial designs applied to PM, which we classified into four core categories (namely, Master protocol, Randomise-all, Biomarker strategy and Enrichment). We found 131 clinical trials using these designs, of which the great majority were master protocols (86/131, 65.6%). Most of the trials were phase II studies (75/131, 57.2%) in the field of oncology (113/131, 86.3%). We identified 34 main features of trial designs regarding different aspects (eg, framework, control group, randomisation). The four core categories and 34 features were merged into a double-entry table to create a new classification of trial designs for PM. Conclusions A variety of trial designs exists and is applied to PM. A new classification of trial designs is proposed to help readers to navigate the complex field of PM clinical trials.